|
FXN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.336300042316E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.17819995373958E-09 |
| Normal-vs-Stage2 |
9.828500E-02 |
| Normal-vs-Stage3 |
5.90769999586627E-09 |
| Normal-vs-Stage4 |
9.1214036324061E-11 |
| Stage1-vs-Stage2 |
7.037700E-03 |
| Stage1-vs-Stage3 |
2.758600E-01 |
| Stage1-vs-Stage4 |
5.204600E-03 |
| Stage2-vs-Stage3 |
8.354200E-04 |
| Stage2-vs-Stage4 |
4.22469999999953E-05 |
| Stage3-vs-Stage4 |
8.472300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.16260034721938E-10 |
| Normal-vs-AfricanAmerican |
1.824090E-02 |
| Normal-vs-Asian |
6.87100043528233E-10 |
| Caucasian-vs-AfricanAmerican |
5.217600E-01 |
| Caucasian-vs-Asian |
6.104400E-02 |
| AfricanAmerican-vs-Asian |
1.664810E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03800000039733E-07 |
| Normal-vs-Female |
4.85700002439415E-09 |
| Male-vs-Female |
6.057400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.03620009742167E-10 |
| Normal-vs-Age(41-60Yrs) |
3.20819999455324E-08 |
| Normal-vs-Age(61-80Yrs) |
9.54530000000231E-05 |
| Normal-vs-Age(81-100Yrs) |
1.945520E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.029000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.646240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.030000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.712600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.170000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.771400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.723700E-03 |
| Classical-VS-Follicular |
1.91182000000012E-05 |
| Classical-VS-Other |
5.618000E-01 |
| Classical-VS-Normal |
2.15329976072098E-11 |
| Tall-VS-Follicular |
2.49379999983645E-08 |
| Tall-VS-Other |
2.061200E-01 |
| Tall-VS-Normal |
7.16100512221374E-11 |
| Follicular-VS-Other |
3.642600E-01 |
| Follicular-VS-Normal |
6.380300E-02 |
| Other-VS-Normal |
5.046000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.04260000000023E-05 |
| Normal-vs-N1 |
8.27989898866122E-11 |
| N0-vs-N1 |
1.152580E-04 |
|
|
